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Abstract
Introduction Survivors from sepsis have presented with long-
term cognitive impairment, including alterations in memory,
attention, concentration, and global loss of cognitive function.
Thus, we evaluated the effects of memory enhancers in sepsis-
surviving rats.
Methods The rats underwent cecal ligation and perforation
(CLP) (sepsis group) with 'basic support' (saline at 50 mL/kg
immediately and 12 hours after CLP plus ceftriaxone at 30 mg/
kg and clindamycin at 25 mg/kg 6, 12, and 18 hours after CLP)
or sham-operated (control group). After 10 or 30 days, rats were
submitted to an inhibitory avoidance task. After task training,
animals received injections of saline, epinephrine, naloxone,
dexamethasone, or glucose. Twenty-four hours afterwards,
animals were submitted to the inhibitory avoidance test.
Results We demonstrated that memory enhancers reversed
impairment in the sepsis group 10 and 30 days after sepsis
induction. This effect was of lower magnitude when compared
with sham animals 10 days, but not 30 days, after sepsis.
Conclusions Using different pharmacologic approaches, we
conclude that the adrenergic memory formation pathways are
responsive in sepsis-surviving animals.
Introduction
Central nervous system dysfunction secondary to sepsis can
occur in 8% to 70% of septic patients [1]. In addition, it has
been demonstrated that survivors from sepsis presented long-
term cognitive impairment, including alterations in memory,
attention, concentration, and global loss of cognitive function
[2]. However, the mechanisms associated with these altera-
tions are still unclear. We had previously demonstrated that
sepsis survivors after 10 and 30 days of cecal ligation and per-
foration (CLP) presented memory impairment and behavior
alterations, and we proposed this model as a useful tool to
determine the mechanisms associated with long-term cogni-
tive impairment in sepsis survivors [3-7].
Aversively motivated learning is influenced by neuromodula-
tors and hormones related to emotional aspects of the training
experience. Emotionally arousing events cause a release of
epinephrine (EPI) and an increase in corticosterone, and both
EPI and corticosteroids are known to modulate memory [8].
Other systems could modulate the formation of emotionally
motivated memory. For example, opioid receptors are involved
in memory modulation, and post-training injections of the opi-
oid antagonist naloxone (NAL) enhance retention of inhibitory
avoidance in rats [9]. In this context, we investigated whether
some of the molecular mechanisms associated with memory
formation are preserved in sepsis survivors using the post-
training administration of EPI, NAL, dexamethasone (DEX),
and glucose (GLU) in a step-down inhibitory avoidance task in
rats.
CLP: cecal ligation and perforation; DEX: dexamethasone; EPI: epinephrine; GLU: glucose; NAL: naloxone.Critical Care    Vol 12 No 5    Tuon et al.
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Materials and methods
Animals
Two hundred forty adult male Wistar rats (220 to 300 g) were
obtained from our breeding colony. They were housed five to
a cage with food and water available ad libitum and were main-
tained on a 12-hour light/dark cycle (lights on at 7 a.m.).
Behavioral procedures were conducted between 8 a.m. and
noon. All experimental procedures involving animals were per-
formed in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals [10] and
the Brazilian Society for Neuroscience and Behavior (SBNeC)
recommendations for animal care, and approval for the study
was given by the ethics committee from our university.
Cecal ligation and perforation surgery
Animals were subjected to CLP as described [11] with adap-
tations [12-14]. Briefly, rats were anesthetized with a mixture
of ketamine (80 mg/kg) and xylazine (10 mg/kg) given intra-
peritoneally. Under aseptic conditions, a 3-cm midline laparot-
omy was performed to allow exposure of the cecum with the
adjoining intestine. The cecum was tightly ligated with a 3.0
silk suture at its base, below the ileocecal valve, and was per-
forated once with a 14-gauge needle. The cecum was then
gently squeezed to extrude a small amount of feces from the
perforation site returned to the peritoneal cavity, and the
laparotomy was closed with 4.0 silk sutures. Animals were
resuscitated with normal saline (50 mL/kg subcutaneously)
immediately and 12 hours after CLP. All animals were returned
to their cages with free access to food and water. In the sham-
operated group, the rats were submitted to all surgical proce-
dures but the cecum was neither ligated nor perforated. After
surgery, the sepsis group received 'basic support' (30 mg/kg
ceftriaxone and 25 mg/kg clindamycin subcutaneously every 6
hours for a total of 3 days). The sham-operated group received
the volume of saline corresponding to antibiotic administra-
tion. Survival rates were 100% in the sham group and 47% in
the sepsis group, which were in accordance with our previous
reports [12-14]. Animals were randomly distributed to sham
and CLP groups and to memory enhancers or saline, and 10
or 30 days after surgery the animals underwent an inhibitory
avoidance test.
Inhibitory avoidance
The inhibitory avoidance procedure was described in a previ-
ous report [15]. The apparatus was an acrylic box (50 × 25 ×
25 cm) whose floor consisted of parallel-caliber stainless-steel
bars (1 mm diameter) spaced 1 cm apart, and a platform that
was 7 cm wide and 2.5 cm high. Animals were placed on the
platform and their latency to step down on the grid with all four
paws was measured with an automatic device. Training ses-
sions were performed 10 or 30 days after surgery. Immediately
after stepping down on the grid, animals received a foot shock
of 0.3 mA and 2 seconds. In test sessions carried out 24 hours
after training, no foot shock was given and the step-down
latency (maximum of 180 seconds) was used as a measure of
retention. The behavioral tests were performed by the same
person that was blind to the experimental group.
Intervention
The animals were divided in groups of 15 and received an
intraperitoneal injection of saline (control), EPI (25 μg/kg),
NAL (0.4 mg/kg), DEX (0.3 mg/kg), or GLU (320 mg/kg)
immediately after training. The doses were selected based on
a previous report [15].
Statistical analyses
Data for inhibitory avoidance are presented as the median
(interquartile range) of retention test latencies. Differences
between training and test session latencies within each group
were determined using the Wilcoxon test. The Kruskal-Wallis
test was performed in comparisons between groups. For com-
parisons between various treatments, the Mann-Whitney test
with the Bonferroni adjustment modified by Finner was used.
Results
As expected, classical memory enhancers EPI (Z = -3.05, P =
0.002 for both 10 and 30 days after surgery, comparing train-
ing and test), NAL (Z = -3.06, P = 0.002 for both 10 and 30
days after surgery, comparing training and test), DEX (Z = -
3.05, P = 0.002 for both 10 and 30 days after surgery, com-
paring training and test), or GLU (Z = -3.06, P = 0.002 for
both 10 and 30 days after surgery, comparing training and
test) improved memory in the inhibitory avoidance 10 and 30
days after sham surgery (Figures 1 and 2). Ten days after CLP,
EPI (Z = -3.18, P = 0.001, comparing training and test), NAL
(Z = -3.06, P = 0.002, comparing training and test), DEX (Z =
-3.06, P = 0.002, comparing training and test), or GLU (Z = -
3.06, P = 0.002, comparing training and test) reversed mem-
ory impairment but this effect was of lower magnitude when
compared with sham animals (Figure 1) (Additional data file 1).
In addition, memory enhancers reversed memory impairment
30 days after sepsis induction in the same magnitude when
compared with sham animals (Z = -3.18, P = 0.001 to EPI,
comparing training and test; Z = -3.06, P = 0.002 to NAL,
comparing training and test; Z = -2.93, P = 0.003 to DEX,
comparing training and test; Z = -3.06, P = 0.002 to GLU,
comparing training and test) (Figure 2) (Additional data file 1).
Discussion
The present study demonstrated that the administration of
memory enhancers (EPI, NAL, DEX, or GLU) in sepsis survi-
vors reverses long-term cognitive impairment. These results
suggest that, instead of the demonstrated neuronal loss after
sepsis [16], the molecular mechanisms associated with affec-
tive memory formation are preserved in sepsis survivors. The
effect of cognitive enhancers seemed to be of a different mag-
nitude 10 or 30 days after sepsis, suggesting that the mecha-
nisms responsible for affective memory formation were more
compromised early after sepsis recovery. This observation is
consistent with our previous results that demonstrated a time-Available online http://ccforum.com/content/12/5/R133
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dependent recuperation of memory deficits in sepsis-surviving
rats [3-7]. We had previously demonstrated that survivors from
sepsis presented habituation and non-aversive and aversive
memory deficits [3-7], but the results presented here are lim-
ited to aversive (affective) memory, which has several charac-
teristics that are very different than declarative, procedural, or
Figure 1
Inhibitory avoidance task 10 days after cecal ligation and perforation (CLP) Inhibitory avoidance task 10 days after cecal ligation and perforation (CLP). Animals were submitted to CLP or were placed in a sham-operated 
group. Ten days after surgery, animals underwent the training test for an inhibitory avoidance task. Immediately after training, animals received a sin-
gle injection of saline (SAL), epineohrine (EPI), naloxone (NAL), dexamethasone (DEX), or glucose (GLU), and animals were tested 24 hours later. 
Data are presented as median (interquartile range) of retention test latencies. *Significantly different between training and test, P < 0.05, Wilcoxon 
test. **Significantly different between NAL, GLU, EPI, or DEX and SAL in the test section, P < 0.05, Mann-Whitney test (Kruskal-Wallis chi-square 
13.4, P = 0.009). #Significantly different between sham and CLP in the test section, P < 0.05, Mann-Whitney test (Kruskal-Wallis chi-square 27.48, 
P < 0.001).
Figure 2
Inhibitory avoidance task 30 days after cecal ligation and perforation (CLP) Inhibitory avoidance task 30 days after cecal ligation and perforation (CLP). Animals were submitted to CLP or were placed in a sham-operated 
group. Thirty days after surgery, animals underwent the training test for an inhibitory avoidance task. Immediately after training, animals received a 
single injection of saline (SAL), epineohrine (EPI), naloxone (NAL), dexamethasone (DEX), or glucose (GLU), and animals were tested 24 hours after. 
Data are presented as median (interquartile range) of retention test latencies. *Significantly different between training and test, P < 0.05, Wilcoxon 
test. **Significantly different between NAL, GLU, EPI, or DEX and SAL in the test section, P < 0.05, Mann-Whitney test (Kruskal-Wallis chi-square 
27.7, P < 0.001). #Significantly different between sham and CLP in the test section, P < 0.05, Mann-Whitney test (Kruskal-Wallis chi-square 30.8, 
P = 0.001).Critical Care    Vol 12 No 5    Tuon et al.
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instrumental memory [17].
Several studies have found alterations in neurocognitive func-
tion following critical illness [18-23], and recognition of these
long-term sequelae in survivors from critical illnesses has
shifted outcome values from reduction in hospital mortality to
patient-centered outcomes [24]. However, to date, the mech-
anisms associated with these alterations are still unclear; thus,
animal models can be used to address these limitations.
Explicitly or implicitly, learning tasks in animals involve the per-
formance or the inhibition of some form of movement in
response to sensory or other cues. Of the various training pro-
cedures used, perhaps the most popular in the past few years
have been the Morris water maze, one-trial inhibitory avoid-
ance, and various forms of fear conditioning, all of which
closely mimic human situations of daily life. The inhibitory
avoidance task relies heavily on the dorsal hippocampus but
also depends on the entorhinal and parietal cortex and is mod-
ulated by the amygdale [25,26]. In this way, we believe that
our results, using the CLP model, provide relevant insights into
the mechanisms involved in the cognitive deficits associated
with sepsis and into therapeutic approaches to this problem.
None of the neuropsychological tests that are used in humans,
however, assessed memory of this sort. Rather, cognitive
assessments evaluated patients on measures of, for example,
declarative memory and working memory. Recognition of
objects is thought to be a critical component of human declar-
ative memory that is mainly dependent on the hippocampus.
Object recognition is commonly impaired in human patients
affected by neurodegenerative diseases or who have suffered
brain injury [27,28]. In addition, executive functions are medi-
ated by independent and interacting neural systems that may
be compromised by different forms of pathology, leading to a
range of cognitive profiles. The frontostriatal network mediates
those cognitive functions that are needed to optimize perform-
ance in complex tasks and that include a number of psycho-
logical processes. Recognition memory was previously
demonstrated to be altered in animal models of sepsis [5], but
there were no published data that assessed executive mem-
ory. Therefore, future animal studies that test the effect of crit-
ical illness on cognitive functions should employ outcomes
that assess functioning in homologous systems in animals
involving the frontal lobe and/or hippocampus as is observed
in humans.
All the used memory enhancers seemed to exert their effect by
modulating the adrenergic system, and there is evidence that
catecholamine has profound effects on cognitive function
[29]. Immediate post-training systemic injections of EPI or
norepinephrine enhance the consolidation and/or storage of
novel information in rats [29]. The enhancing effects of gluco-
corticoids on memory consolidation depend on the integrity of
the amygdala noradrenergic system [30] as do the enhancing
effects of NAL [31]. The effects of the noradrenergic system
on memory formation seemed to be dependent on GLU since
a noradrenergic agonist enhances memory formation by facili-
tation of GLU uptake at the time of memory consolidation [32].
These effects are not restricted to animal models. Recent evi-
dence indicates that EPI enhances memory consolidation in
humans [33]. In addition, it is now well established that gluco-
corticoid hormones enhance memory consolidation [34] and
that GLU modulates memory formation in humans [35]. Opioid
peptides mediate alterations in human memory during emo-
tional states and help to explain why memories may be selec-
tively deficient under conditions of stress [36]. Thus, since
survivors from the intensive care unit presented long-term cog-
nitive impairment, including alterations in memory, and this
was associated with a decrease in quality of life [23], our
results brings the perspective to improve long-term outcome
in sepsis survivors.
Some limitations of our study must be pointed out. First, septic
animals in comparison with sham controls received antibiotics,
which could have neuroprotective properties [37]. We had
demonstrated previously that the antibiotics used in our model
did not modify memory performance in our model [4]; thus, we
believe that this limitation is of minor importance. Second, it
would be interesting to examine the effects of other drugs that
are more promising as clinically useful cognitive enhancers
(that is, rolipram) [38], but since this is the first demonstration
of enhancing memory after CLP, we decided to use more
'classical' memory enhancers. Third, only single doses of the
memory enhancers were evaluated; thus, instead of a normal
response observed using these doses, we could not rule out
the possibility that in sepsis survivors the dose response curve
to these enhancers may be altered. Fourth, we demonstrated
that sepsis altered memory of an emotional event (that is, foot
shock). One may suggest that the response to a new stimulus
depends on the intensity of a previous emotional challenge
and that we are not observing a true sepsis effect, but a pro-
cedure-related effect. We tried to avoid this limitation by ran-
domly dividing animals between groups, and animals were
subjected to the same surgical procedure, with sepsis being
the sole difference between groups. There are also some
clues that suggest that animals are similar in regard to stress
response. First, in the open-field task, there were no differ-
ences in the number of crossings and rearings between
groups in the training session, demonstrating no difference in
motor and exploratory activities between groups [3,4], and
stressed animals presented alterations in the exploratory activ-
ity [39]. Second, in analyses at 10 and 30 days after CLP,
sham and septic animals presented no differences in foot
shock sensitivity as assessed by the 'flinch and jump'
response test [40].
Conclusion
We demonstrated, for the first time, using different pharmaco-
logic approaches, that the adrenergic system is responsive in
sepsis-surviving animals in different intensities 10 and 30 daysAvailable online http://ccforum.com/content/12/5/R133
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after sepsis. Since this system is relevant to memory formation
in humans and animals, our results brings the perspective that
the modulation of the adrenergic system could be a suitable
tool in the treatment of memory deficits observed in sepsis
survivors.
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